{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Sylvain Guérin, CUO-Recherche"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA850000"],"scientific_name":["Homo sapiens"],"tag":["xref:PubMed:36139479"],"long_description":["The objective of this study was to find deregulated genes between healthy and psoriatic T cell-enriched tissue-engineered models to develop a new therapeutic pathway in psoriasis treatment. In this study, we used a tissue-engineered, two-layers (dermis and epidermis) human skin substitute enriched in T cells as a biomaterial to study both the cellular and molecular mechanisms involved in psoriasis’ pathogenesis. Overall design: 3 human healthy keratinocytes population (at passage 3) from 3 healthy donors (18-, 46- and 49-years old), 4 human psoriatic keratinocytes population (at passage 3) from directly into the lesion of 4 psoriatic patients (36-, 46-, 49- and 64- years old) and 3 human psoriatic keratinocytes population (at passage 3) from area without lesion of three psoriatic patients (46-, 49- and 64- years old) co-cultured or not with T-lymphocyte from human tissue-engineered skin substitutes are analyzed by gene profiling."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Gene expression in human keratinocytes from psoriatic skin (directly into the lesion or in area without lesion) or healthy person (control) used for human tissue-engineered skin substitutes and co-cultured with T-lymphocyte","description":"Gene expression in human keratinocytes from psoriatic skin (directly into the lesion or in area without lesion) or healthy person (control) used for human tissue-engineered skin substitutes and co-cultured with T-lymphocyte","dates":{"last_updated":"2025-09-24","first_public":"2022-06-19"},"accession":"PRJNA850000","cross_references":{"GEO":["GSE206311"],"taxon":["9606"],"PubMed":["36139479"]}}